Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Intangibles: 2022-2025

Historic Intangibles for Catalyst Pharmaceuticals (CPRX) over the last 3 years, with Sep 2025 value amounting to $227.7 million.

  • Catalyst Pharmaceuticals' Intangibles changed negligibly% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $227.7 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Intangibles stood at $227.7 million, which was down 0.00% from $227.7 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Intangibles peaked at $227.7 million during Q4 2023, and registered a low of $32.5 million during Q4 2022.
  • Moreover, its 3-year median value for Intangibles was $227.7 million (2025), whereas its average is $209.6 million.
  • Data for Catalyst Pharmaceuticals' Intangibles shows a peak YoY surged of 601.28% (in 2023) over the last 5 years.
  • Catalyst Pharmaceuticals' Intangibles (Quarterly) stood at $32.5 million in 2022, then soared by 601.28% to $227.7 million in 2023, then remained steady at $227.7 million in 2024, then remained steady at $227.7 million in 2025.
  • Its Intangibles was $227.7 million in Q3 2025, compared to $227.7 million in Q2 2025 and $227.7 million in Q1 2025.